BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2007

View Archived Issues

New pharmacokinetic data on iloperidone available

Read More

Respiratory tract-delivered vaccine confers protection against Ebola virus infection in monkeys

Read More

Takeda terminates development of fixed dose Actos + TAK-536 product

Read More

AtheroGenics to focus on diabetes for AGI-1067

Read More

FDA outlines data requirements for Provenge BLA approval

Read More

Treatment completed in prophylactic phase III trial of C1-INH for HAE

Read More

Venticute awarded fast track designation

Read More

Positive topline phase Ib findings for bavituximab in advanced cancers

Read More

Amgen to acquire Ilypsa

Read More

BNC-105 shows preclinical efficacy in prostate tumors

Read More

MF-101 reduces frequency and severity of postmenopausal hot flashes

Read More

Coronado licenses rights from Burnham to develop and commercialize Apogossypol

Read More

NIAID grant supports work on fungal antigens in chronic sinusitis

Read More

R&D highlights from BIO 2007 in Boston: Zealand Pharma

Read More

R&D highlights from BIO 2007 in Boston: BioInvent International

Read More

New vascular-targeting agent moves forward to phase II trials based on positive phase I findings

Read More

Encouraging findings emerge from first-in-man trial of peptibody AMG-386

Read More

First-in-human study of a potent pan-HER tyrosine kinase inhibitor from Pfizer

Read More

Positive results for DNA vaccine adjuvant Vaxfectin in nonhuman primates

Read More

Phase I study suggests promise for orally active VEGFR/FGFR tyrosine kinase inhibitor

Read More

CX-3543, Cylene's lead rDNA biogenesis inhibitor, discussed at ASCO

Read More

Audit to be performed on phase III trial results of PreHistin

Read More

BAY-73-4506, a multikinase inhibitor, active and well tolerated in advanced cancer

Read More

Valeant's retigabine moves towards phase II study in PHN

Read More

Recent sanofi-aventis and Kumamoto University patents impart new agents for autoimmune diseases

Read More

Priority review for Abilify in pediatric schizophrenia

Read More

Biovest to seek conditional approval of BiovaxID

Read More

Novel diagnostic agents reported in recent GE Healthcare patent

Read More

Divigel approved to treat menopausal hot flashes

Read More

Recent Helperby and 3M patents disclose new antiinfective agents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing